Enterprise Value
749.3M
Cash
522.5M
Avg Qtr Burn
-16.07M
Short % of Float
1.32%
Insider Ownership
12.00%
Institutional Own.
94.12%
Qtr Updated
09/30/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Baxdrostat Details Pulmonary hypertension | Phase 3 Initiation | |
Baxdrostat Details Primary aldosteronism (PA) | Phase 2 Data readout | |
Phase 2 Data readout |